Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
1 recherche sur le mot-clé 'or the'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder / Sarah A. KEIM in Journal of Autism and Developmental Disorders, 52-12 (December 2022)
[article]
Titre : Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur Année de publication : 2022 Article en page(s) : p.5342-5355 Langues : Anglais (eng) Mots-clés : Child Child, Preschool Humans Autism Spectrum Disorder/drug therapy Biomarkers Dietary Supplements Double-Blind Method Fatty Acids, Omega-3/therapeutic use Fatty Acids, Omega-6/therapeutic use Interleukin-2/metabolism Autism spectrum disorder Il-2 Inflammation Omega-3 fatty acids Omega-6 fatty acids Young child the content of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Nordic Naturals provided the investigational product at no cost and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither the study sponsors nor product providers had a role in the study design the collection, analysis, and interpretation of data writing of this report or the decision to submit the manuscript for publication. Index. décimale : PER Périodiques Résumé : This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6Â years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90Â days based on participant weight. Erythrocyte FAs and the cytokines, IL-1Î2, IL-2, IFNÎ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40Â mol% for EPA and 1.62Â mol% for DHA) and reduced IL-2 levels compared to placebo (-Â 0.17Â pg/mL, 95% CI -Â 0.31, -Â 0.02, d=-Â 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209. En ligne : http://dx.doi.org/10.1007/s10803-021-05396-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489
in Journal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355[article] Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur . - 2022 . - p.5342-5355.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355
Mots-clés : Child Child, Preschool Humans Autism Spectrum Disorder/drug therapy Biomarkers Dietary Supplements Double-Blind Method Fatty Acids, Omega-3/therapeutic use Fatty Acids, Omega-6/therapeutic use Interleukin-2/metabolism Autism spectrum disorder Il-2 Inflammation Omega-3 fatty acids Omega-6 fatty acids Young child the content of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Nordic Naturals provided the investigational product at no cost and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither the study sponsors nor product providers had a role in the study design the collection, analysis, and interpretation of data writing of this report or the decision to submit the manuscript for publication. Index. décimale : PER Périodiques Résumé : This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6Â years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90Â days based on participant weight. Erythrocyte FAs and the cytokines, IL-1Î2, IL-2, IFNÎ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40Â mol% for EPA and 1.62Â mol% for DHA) and reduced IL-2 levels compared to placebo (-Â 0.17Â pg/mL, 95% CI -Â 0.31, -Â 0.02, d=-Â 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209. En ligne : http://dx.doi.org/10.1007/s10803-021-05396-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489